Dublin, Dec. 06, 2018 (GLOBE NEWSWIRE) -- The "Global Anti-obesity Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.
The anti-obesity drugs market is projected to register a CAGR of almost 8% by 2023.
The research on drugs that target obesity and type 2 diabetes mellitus to gain traction in the market. The global epidemic obesity and type 2 diabetes is increasing. This demands for increasing focus on the drugs that can control obesity and diabetes.
Global increase in both incidence and prevalence of obesity
The prevalence and incidence rate of obesity is very high because of the limited efficacy of currently available drugs. The prevalence of obesity remains the highest in the US over the past two decades. Thus, the shoot in the rates of obesity across the world offers huge opportunities for drug manufacturing vendors to manufacture innovative and highly effective drugs.
Limited reimbursement for anti-obesity drugs
Although US is the major market for anti-obesity drugs, the challenges associated with the reimbursement of these drugs is more in the US. The bariatric surgery can recover weight related issues and is life-saving, but the concern for financial burden remains. People are unwilling to pay for this surgery as they believe that obesity is a cosmetic or lifestyle issue, which led player limit coverage.
Competitive Landscape
The market appears to be concentrated and with the presence of few companies including Eisai and Novo Nordisk the competitive environment is quite intense. Factors such as the increase in childhood obesity incidence and the use of implantable neuroregulatory devices for treating obesity, will provide considerable growth opportunities to anti-obesity drugs manufactures.
Key Players
With the presence of a considerable number of companies, this market appears to be fragmented. This market to witness the presence of a few international and regional anti-obesity drug companies who offer obesity treatment drugs for mechanism such as centrally-acting and peripherally-acting anti-obesity drugs.
Key Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE ANALYSIS
PART 08: MARKET SEGMENTATION BY DRUGS BASED ON CLASS OF OBESITY
PART 09: MARKET SEGMENTATION BY MECHANISM OF ACTION
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
PART 16: VENDOR ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/research/5b72hc/global?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.